Floatz logo

Ati-0918

Malignant Female Reproductive System Neoplasm

Azaya Therapeutics, Inc.Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

52 Active assets in the Malignant Female Reproductive System Neoplasm cohort.

Asset / SponsorPhaseRating
Inno-206
AstraZeneca
Phase 2BB
Carboplatin
AbbVie
Phase 2/3BB
Indocyanine Green
Istanbul University
Phase 4BB
NORMAL HUMAN SERUM ALBUMIN
Joachim Zdolsek
Phase 4B
Ipilimumab
M.D. Anderson Cancer Center
Phase 2B

View all 50 →

Same molecule, other indications

Ati-0918 is also rated in:

ovarian neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
ovarian carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
cancerDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →